Skip to main content
SpringerLink
Log in

Industry Pulse

Editorial Development By Adis International Limited, Italy

  • Industry Pulse
  • Published:
High Blood Pressure & Cardiovascular Prevention Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

Section 2

  1. Dahlof B, Devereux RB, de Faire U, et al. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group. Am J Hypertens 1997; 10(7 Pt 1): 705–13

    PubMed  CAS  Google Scholar 

  2. Wachtell K, Lehto M, Gerdts E, et al. Angiotensin II receptor blockade reduces newonset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005; 45(5): 712–9

    Article  PubMed  CAS  Google Scholar 

  3. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995–1003

    Article  PubMed  CAS  Google Scholar 

  4. Wachtell K, Hornestam B, Lehto M, et al. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005; 45(5): 705–11

    Article  PubMed  Google Scholar 

  5. Pedersen OD, Bagger H, Kober L, et al. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999; 100: 376–80

    Article  PubMed  CAS  Google Scholar 

  6. Vermes E, Tardif JC, Bourassa MG, et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 2003; 107: 2926–31

    Article  PubMed  Google Scholar 

  7. Bourassa MG. Angiotensin II inhibition and prevention of atrial fibrillation and stroke. J Am Coll Cardiol 2005; 45(5): 720–1

    Article  PubMed  CAS  Google Scholar 

  8. Narayan SM, Cain ME, Smith JM. Atrial fibrillation. Lancet 1997; 350: 943–50

    Article  PubMed  CAS  Google Scholar 

Section 4

  1. Gosse P, Neutel J, Schumacher H, et al. Reduction of early morning blood pressure surge with telmisartan compared with ramipril in mild-to-moderate hypertensive patients [poster P3.355]. J Hypertens 2005; 23Suppl. 2: S375–6

    Google Scholar 

  2. Williams B, Lacourciere Y, Schumacher H, et al. Telmisartan versus ramipril in 24-h ambulatory blood pressure: a pooled analysis of 2 prospective, randomized trials in mildto- moderate hypertensive patients [poster P3.372]. J Hypertens 2005; 23Suppl. 2: S380

    Google Scholar 

  3. Yang S. The power of circadian rhythms [online]. http://my.webmd.com/content/Article/11/1674_50522.htm [Accessed 2005 Oct 1]

  4. Elliott WJ. Circadian variation in the timing of stroke onset: a meta-analysis. Stroke 1998; 29: 992–6

    Article  PubMed  CAS  Google Scholar 

  5. Kario K. Morning surge and variability in blood pressure: a new therapeutic target? Hypertension 2005; 45: 485–6

    Article  PubMed  CAS  Google Scholar 

  6. Kario K. Time for focus on morning hypertension: pitfall of current antihypertensive medication. Am J Hypertens 2005; 18: 149–51

    Article  PubMed  Google Scholar 

  7. Marfella R, Siniscalchi M, Nappo F, et al. Regression of carotid atherosclerosis by control of morning blood pressure peak in newly diagnosed hypertensive patients. Am J Hypertens 2005; 18: 308–18

    Article  PubMed  Google Scholar 

  8. 2003 European Society of Hypertension. European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011–53

  9. Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet 2000; 355: 637–45

    Article  PubMed  CAS  Google Scholar 

  10. Brunner HR. The new oral angiotensin II receptor antagonist olmesartan medoxomil: a concise overview. J Hum Hypertens 2002; 16Suppl. 2: S13–6

    Article  PubMed  CAS  Google Scholar 

  11. Lewington S, Clark R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360(9349): 1903–13

    Article  PubMed  Google Scholar 

  12. Neutel JM, Smith DH. Evaluation of angiotensin II receptor blockers for 24 hour blood pressure control: meta-analysis of a clinical database. J Clin Hypertens (Greenwich) 2003; 5(1): 58–63

    Article  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Industry Pulse. High Blood Press Cardiovasc Prev 12, 195–198 (2005). https://doi.org/10.2165/00151642-200512030-00174

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151642-200512030-00174

Search

Navigation